Immunotherapies in phase II and III trials for the treatment of systemic lupus erythematosus-Reference-Cited by-同舟云学术

Immunotherapies in phase II and III trials for the treatment of systemic lupus erythematosus

Published:2016-11-18 Issue:1 Volume:5 Page:55-69
ISSN:2167-8707
Container-title:Expert Opinion on Orphan Drugs
language:en
Short-container-title:Expert Opinion on Orphan Drugs

Author:

Radin Massimo¹,Cecchi Irene¹,Schreiber Karen²³,Baldovino Simone¹,Rossi Daniela¹,Menegatti Elisa¹,Roccatello Dario¹,Sciascia Savino¹

Affiliation:

1. Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, and SCDU Nephrology and Dialysis, S. Giovanni Bosco Hospital

2. Department of Thrombosis and Thrombophilia, Guy’s and St Thomas’ Hospital, London, UK

3. Department of Rheumatology, Copenhagen University Hospital at Rigshospitalet, Copenhagen, Denmark

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Link

https://www.tandfonline.com/doi/pdf/10.1080/21678707.2017.1257937

Reference116 articles.

1. The efficacy of novel B cell biologics as the future of SLE treatment: A review

2. Systemic Lupus Erythematosus

3. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity

4. Distinguishing Features of Anti-β2 Glycoprotein I Antibodies between Patients with Leprosy and the Antiphospholipid Syndrome

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Open-label, prospective, phase II descriptive pilot trial of belimumab therapy for refractory and/or non-criteria manifestations of antiphospholipid syndrome: study protocol;Clinical and Experimental Rheumatology;2022-01-10

2. Long-term effect of B-cells depletion alone as rescue therapy for severe thrombocytopenia in primary antiphospholipid syndrome;Seminars in Arthritis and Rheumatism;2019-02

3. Anticardiolipin and anti-beta 2 glycoprotein-I antibodies disappearance in patients with systemic lupus erythematosus and antiphospholipid syndrome while on belimumab;Annals of the Rheumatic Diseases;2018-05-18